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Background: TRAIL induces apoptosis through interaction with receptor DR5.
Results: Animal model of neonatal hypoxia-ischemia (HI) and primary cultures subjected to oxygen glucose deprivation show
increased expression of TRAIL and DR5; TRAIL is toxic for primary neurons.
Conclusion: TRAIL-mediated cell death contributes to brain injury after HI.
Significance: TRAIL signaling pathways may represent a valid drug target for protection against neonatal HI.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF family. The interaction of
TRAILwith death receptor 4 (DR4) andDR5 can trigger apopto-
tic cell death. The aim of this study was to investigate the role of
TRAIL signaling in neonatal hypoxia-ischemia (HI). Using a
neonatal mouse model of HI, mRNA, and protein expression of
TRAIL, DR5 and the TRAIL decoy receptors osteoprotegerin
(OPG), mDcTRAILR1, and mDcTRAILR2 were determined. In
vitro, mRNAexpression of these geneswasmeasured in primary
neurons and oligodendrocyte progenitor cells (OPCs) after
inflammatory cytokine (TNF-/IFN-) treatment and/or oxy-
gen and glucose deprivation (OGD). The toxicity of these vari-
ous paradigms was also measured. The expression of TRAIL,
DR5, OPG, and mDcTRAILR2 was significantly increased after
HI. In vitro, inflammatory cytokines and OGD treatment
significantly induced mRNAs for TRAIL, DR5, OPG, and
mDcTRAILR2 in primary neurons and of TRAIL and OPG in
OPCs. TRAIL protein was expressed primarily in microglia and
astroglia, whereas DR5 co-localized with neurons and OPCs in
vivo. OGD enhanced TNF-/IFN- toxicity in both neuronal
and OPC cultures. Recombinant TRAIL exerted toxicity alone
or in combinationwithOGDandTNF-/IFN- in primary neu-
rons but not in OPC cultures. The marked increases in the
expression of TRAIL and its receptors after cytokine exposure
and OGD in primary neurons and OPCs were similar to those
found in our animal model of neonatal HI. The toxicity of
TRAIL in primary neurons suggests that TRAIL signaling par-
ticipates in neonatal brain injury after inflammation and HI.
Hypoxia-ischemia (HI)2 is an important cause of perinatal
brain injury both in term infants suffering from intrapartum
asphyxia and in preterm infants exposed to hypotensive events
(1, 2). The pathophysiological mechanisms are complex and
processes such as apoptosis, necroptosis, mitochondrial
impairment, oxidative stress, and inflammation are involved
(3). There are several lines of evidence that inflammation
induces cell death after HI (4). However, we lack the molecular
understanding of how immuno-inflammatory mediators pro-
voke death of neurons and oligodendroglial precursor cells
(OPCs) in neonatal HI. During inflammation, both infiltrating
immune cells and resident CNS glial cells produce reactive oxy-
gen species, release excitatory amino acid agonists, proinflam-
matory cytokines (e.g. IL-1, IL-18, TNF-), chemokines (5, 6),
and tumor necrosis factors (e.g. TNF-, TNF-, FasL, TRAIL,
TWEAK) (5, 7–9).We hypothesized that tumor necrosis factor
superfamilymembers participate in the evolution of injury after
HI because several ligand-receptor pairs belonging to the TNF
family have been implicated in the injurious cascade (10).
Previous work has implicated the TNF- cluster (11) and Fas
signaling (7, 12, 13) in the cellular loss after HI, but little is
known about the role of TRAIL signaling in the development of
neonatal brain injury. In humans, four membrane-bound and
one soluble receptor for TRAIL have been identified. Of these,
two contain cytoplasmic death domains (DR4 and DR5) and
have the capacity to induce apoptotic cell death (14, 15),
whereas DcR1 (TRAIL-R3), DcR2 (TRAIL-R4), and the soluble
osteoprotegerin (OPG) lack functional death domains and are
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considered to function as decoy receptors (16–19). Similar
receptors forTRAIL exist in rodents. There are twomembrane-
spanning decoy receptors, mDcTRAILR1 and mDcTRAILR2
(20), one soluble OPG (19), and only one death-mediating
TRAIL receptor, which has the highest homology with the
human DR5 receptor (21).
TRAIL-DR4/5 can induce apoptosis via Fas-associated pro-
tein with death domain/death-inducing signaling complex
(FADD/DISC)/caspase-8 signaling in several cell types, includ-
ing neurons and oligodendroglia (10). This pathway is impor-
tant in the pathogenesis of adult stroke (22), trauma (23), infec-
tion (24), and multiple sclerosis (25), but there is limited
information availablewith respect to the involvement of TRAIL
and its receptors in the demise of immature neurons such as in
neonatal HI (26).
The aim of the present study is to explore the expression and
the cellular distribution of TRAIL and its binding receptors in
an animal model of neonatal HI; second, to investigate the
induction of TRAIL molecules in vitro in primary neurons and
OPCs after oxygen glucose deprivation (OGD) and/or TNF-/
IFN- administration; and third, to evaluate the cellular toxicity
of TRAIL in these cells.
EXPERIMENTAL PROCEDURES
Neonatal Hypoxia-ischemia—C57BL/6 wild-type mice were
obtained fromMoellegaard Breeding and Research Center A/S
(Skensved, Denmark). Neonatal HI was induced at postnatal
day 9 according to methods described by Rice et al. (27) but
modified for mice (28, 29). Mice of both sexes were anesthe-
tized with isoflurane (3% for induction and 1.5% for mainte-
nance) in nitrous oxide/oxygen (1:1). The left common carotid
artery was ligated with PROLENE suture #6-0 (ETHICON).
After the surgical procedure, the wounds were closed and infil-
trated with a local anesthetic. After 1 or 2 h of recovery with the
dam, the pupswere placed in a chamber perfusedwith a humid-
ified gas mixture (10% oxygen in nitrogen) for 60 min at 36 °C.
The animals were kept in humidified air at 36 °C for extra 10
min before and after the hypoxic exposure. After the hypoxia,
the pups were returned to their dams. This procedure results in
brain injury in the ipsilateral hemisphere consisting of cerebral
infarction and selective neuronal death in the cortex, striatum,
hippocampus, and the thalamus, leaving the contralateral
hemisphere undamaged. Control littermates were neither
operated on nor subjected to hypoxia. The Animal Ethical
Committee of Gothenburg approved all animal experiments
(no. 269/01). Pups were killed by decapitation at 2, 8, 24, and
72 h after HI and controls at postnatal day 9 and postnatal day
12 (n 5 at each time point). Brains were removed and rapidly
frozen on dry ice. Cortex, hippocampus, thalamus, subcortical
white matter, and striatum were microdissected from each
hemisphere in a frozen state.
Primary Cell Culture—Cell culture medium was purchased
from Invitrogen or Sigma. FBS and all cell culturemedium sup-
plements were purchased from Sigma unless otherwise noted.
Recombinant human FGF-2 and recombinant mouse or rat
TNF- and IFN- were purchased from Peprotech. Recombi-
nant mouse TRAIL was purchased from R&D Systems. TRAIL
was denatured by incubating at 95 °C for 5 min followed by
rapid cooling to 4 °C.
Primary Neurons—Primary cortical neurons were prepared
from C57BL/6 embryonic day 15 mice as described previously
(30). Briefly, cortices from embryos in a single litter were dis-
sected, meninges were removed, and tissue was pooled. Corti-
ces were roughly chopped before incubation in 0.25% trypsin/
EDTA followed by trituration. Cells were pelleted by
centrifugation, resuspended, and plated in Neurobasal medium
supplemented with 1 B27 (Invitrogen), 1 streptomycin/am-
photericin B (Invitrogen), and 300 M glutamine. Treatments
were carried out onmature neurons grown for aminimumof 12
days in vitro.
Primary OPC Culture—OPCs were prepared from newborn
Sprague-Dawley rats as described previously (31). In brief, fore-
brain cortices were removed from postnatal day 0–2 rat pups
and dissected. Tissues were enzymatically digested with DNase
I and 0.25% trypsin and then mechanically dissociated. Cells
were resuspended in minimum essential Eagle’s medium
(Sigma) supplemented with 10% FBS, 2 mM L-glutamine
(Sigma), 100 g/ml penicillin-streptomycin solution (Sigma),
and 0.6% glucose and plated in T75 flasks at a density of 2 
105/cm2. Mixed glial cell cultures were grown for 11 days, and
OPCs were purified using the shakingmethod (32). In brief, the
mixed glial cell culture was shaken for 1.5 h at 260 rpm to
remove microglia, and remaining cells were shaken for 18h to
detach the OPCs from astrocytes. Purified OPCs were seeded
onto poly-D-lysine-coated 60-mm or 24-multiwell plates at a
density of 3 104/cm2 in N2S medium. N2S medium consists
of 66% DMEM/F-12 supplemented with (0.66 mg/ml BSA, 10
ng/ml D-biotin, 5 g/ml insulin, 20 nM progesterone, 100 M
putrescine, 5 ng/ml selenium, 50 g/ml apo-transferrin, 100
g/ml penicillin, 100 g/ml penicillin-streptomycin solution,
and 0.5% FBS) and 34% of the samemedium conditioned by the
B104 neuroblastoma cell line for 3 days, supplemented with 5
ng/ml FGF-2 (Preprotech), and 0.5% FBS. OPCswere amplified
for 6 days before experiments were performed.
OGDand Treatment of Primary Cells—OGDwas induced by
replacing the cellmediumwith artificial cerebrospinal fluid and
incubating the cells in a modular incubator chamber MIC-
101 (Billups-Rothenberg, Inc.) filled with a gas mixture of 5%
CO2 and 95% N2. Cells plated in 24-multiwell dishes (used
for cell death experiments) were subjected to 1 h of OGD,
whereas cells plated in 60-mm dishes (used for RNA extrac-
tion) were subjected to 4 h of OGD. After OGD, the artificial
cerebrospinal fluid was replaced with fresh medium for OPC
and with 50% new:50% preconditioned medium for the
neurons. The medium in the control cells was replaced
correspondingly.
Weoptimized theOGDduration for the primarymouse neu-
rons by conducting time course studies and optimized cytokine
concentrations by performing dose-response studies. Those
studies established that 4 h of OGD induced50% cell death in
the neuronal cultures plated in p60 dishes (data not shown).
Neurons plated in 24-well plates were much more sensitive to
OGD; therefore, we used 1 h for our cell death studies. Cyto-
kines were evaluated at concentrations from 1 ng/ml to 500
ng/ml. None of them displayed toxicity toward neurons; there-
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fore, for our studies we chose 200 ng/ml as we found no differ-
ence in the expression levels of studied proteins between 200
and 500 ng/ml (data not shown).
Treatments with recombinant inflammatory cytokines were
performed after the OGD with final concentrations of 200
ng/ml mouse TNF- and 200 ng/ml mouse IFN- for neurons
and 200 ng/ml rat TNF- and 200 ng/ml rat IFN- for OPCs.
Treatment with 1 g/ml recombinant mouse TRAIL was per-
formed 16 h after the OGD/cytokine treatment. The concen-
tration was chosen after dose response study as the lowest toxic
concentration for neurons (data not shown). All recombinant
proteins were dissolved in PBS.
RNA Isolation—Total RNA from mouse brains was isolated
using the RNeasy mini kit (Qiagen) according to the manufa-
cturer’s instructions. The RNA was quantified by spectropho-
tometry at 260 nm, and the ODwas determined by the 260/280
ratio. The OD of the RNA was between 1.9 and 2.1, and the
quality of the RNAwas further evaluated by electrophoresis on
a 1.1% agarose, 2.2 mol/liter formaldehyde gel to ascertain that
there was no degradation. Six micrograms of total RNA from
neocortex, hippocampus, thalamus, and striatum was thereaf-
ter pooled to represent a gray matter sample for each hemi-
sphere. The same RNA isolation procedure and quality check
was performed for RNA isolated from cell cultures.
Quantitative RT-PCR—The reverse transcription reaction
was performed using a High Capacity cDNA reverse transcrip-
tion kit (Applied Biosystems) according to the manufacturer’s
instructions. Quantitative RT-PCR experiments were per-
formed using the StepOnePlusTM real-time PCR systems,
TaqMan probes, and TaqMan Gene Expression Master Mix
(Applied Biosystems). All reactions were conducted in dupli-
cate and corrected to GAPDH expression. Data were analyzed
using the delta threshold cycle (CT) method.
Western Blot—30 g of total protein lysate per sample was
separated by electrophoresis using 10% Bis-Tris NuPAGE®
Novex gels (Invitrogen) and XCell SureLock® Mini-Cell (Invit-
rogen). Proteins were transferred to polyvinylidene fluoride
membranes using an iBlot® gel transfer device (Invitrogen).
Membranes were blocked with 5% nonfat dry milk in Tris-buff-
ered saline containing 0.1% Tween 20 (TBS-T) and immuno-
blotted overnight at 4 °C with anti-TRAIL antibody (R&D Sys-
tems) or anti-DR5 antibody (R&D Systems) diluted 1:2500 in
TBS-T. After washing with TBS-T, membranes were incubated
for 1 h with HRP-conjugated anti-goat antibody at room temper-
ature. Membranes were washed with TBS-T and developed with
SuperSignalWest Pico chemiluminescent substrate (ThermoLife
Science). The images were taken with ImageQuantTM LAS4000
digital imaging system (GEHealthcare).
Fluorescent Immunohistochemistry—Paraffin-embedded brain
sections were deparaffinized with xylene and ethanol and pre-
treated with heating for 20 min in 10 mM citric acid, pH 6.0,
with 0.1% Tween 20. Sections were blocked for 20 min with 5%
horse serum, 1% BSA in PBS before incubation with primary
antibodies overnight at 4 °C. We used goat anti-TRAIL and
anti-DR5 antibody (R&D Systems) mouse anti-glial fibrillary
acidic protein (GFAP) (Sigma) rabbit anti-Olig2 (Millipore),
Cy3-conjugated NeuN (Millipore), and biotinylated Lycopersi-
con esculentum lectin (Vector). For visualizationwe usedAlexa
Fluor 488-conjugated anti-goat antibody, Alexa Fluor 546 anti-
mouse antibody, and Alexa Fluor 546 streptavidin (Invitrogen).
Sections were analyzed using a Leica DM6000 B fluorescent
microscope and a Leica TCS SP5 confocal microscope. Images
were processed using Leica LAS AF lite and ImageJ software.
The intensity of the TRAIL and DR5 staining in particular cell
typewas assessed for every region of interest (cells with positive
staining for cell type specific marker) and compared with the
overall intensity in the rest of the cells in the image (cells nega-
tive for that particular marker).
Assessing Cell Viability with Methylthiazolyldiphenyl-tetra-
zolium Bromide Assay—Methylthiazolyldiphenyl-tetrazolium
bromide was dissolved in PBS and added to cell medium at a
final concentration of 500 g/ml. After a 30-min (neurons) or
1-h (OPC) incubation, the medium was removed, and the pur-
ple formazan crystals produced by cells were dissolved in
dimethyl sulfoxide. Absorbance was measured at 590 nm on a
spectrophotometer.
Assessing Cell Viability by Counting the Total Number of Via-
ble Cells—Cells were plated on poly-D-lysine-coated chamber
slides (NUNC). After the treatments the cells were stained with
anti-cleaved caspase-3 antibody (Cell Signaling) andDAPI. The
total number of caspase-3 negative nuclei for every condition
was counted using a Leica DM6000 B fluorescent microscope.
Statistical Analysis—Statistical analysis was performed using
Prism GraphPad 5.0 software (Graph-Pad Software). Data are
expressed as means  S.E. Comparisons between the experi-
mental groups were made using one-way analysis of variance
followed by the Dunnett’s (when comparing treatment condi-
tions versus control) or Tukey’s (when comparing the treat-
ments versus control and versus another treatment) post-test or
using two-way analysis of variance followed by Bonferroni post
test, as appropriate.
RESULTS
Neonatal HI Increases the Expression Levels of TRAIL and
TRAIL Receptors—The expression of TRAIL and TRAIL recep-
tors DR5, OPG, mDcTrailR1, and mDcTrailR2 were evaluated
in a neonatal mouse model of unilateral HI. There was a trend
(not statistically significant) of decreasing TRAIL expression
in both hemispheres 2 h after insult, followed by a 3-fold
increase in TRAIL mRNA levels in the ipsilateral compared
with the contralateral side of the brain at 8 and 24 h after HI
(Fig. 1A). The expression of mRNA for DR5 was significantly
induced at 2, 8, 24, and 72 h after HI (Fig. 1B). In addition, the
mRNA expression for mDcTrailR2 and OPG were both
increased at 8 and 72 h after the insult (Fig. 1, D and E),
whereas the levels of mDcTrailR1 remained unchanged (Fig.
1C). There were no significant differences in expression of
any of the genes between the contralateral side of the brain
(exposed to hypoxia) and sham-operated, normoxic animals.
Protein expression was determined at 72 h post insult to
allow earlier mRNA changes to be translated and accumulated
within the cell. As might be expected from the mRNA analysis,
TRAIL and DR5 protein expression was also increased after HI
(Fig. 1, F and G). To investigate which cells were responsible
for the enhanced expression of TRAIL/DR5, we performed
immunofluorescence on brain sections 72 h after HI. For
TRAIL Signaling in Immature CNS after HI and Inflammation
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both proteins, ipsilateral expression was much stronger than
contralateral expression confirming the association of
increased production of TRAIL, DR5, and brain injury (Fig. 2
and see Fig. 3).
TRAIL immunofluorescencewas strongest inGFAP-positive
astrocytes (Fig. 2, A–E) and in lectin-positive microglia (Fig. 2,
F–J), whereas low levels of expression were observed also in
NeuN-positive neurons and in Olig2-positive cells (data not
shown). Thus, we can consider that astrocytes, microglia, and,
to aminor extent, neurons andOPCs accounted together for all
of the TRAIL immunoreactivity. To more rigorously establish
that the astrocytes are predominant sources of TRAIL in the
injured brain, we assessed the intensity of TRAIL staining in
GFAP-positive cells compared with TRAIL staining in GFAP-
negative cells (Fig. 2C). Similar measurements were performed
for microglial cells using the cell-specific marker Lycopersicon
esculentum lectin (Fig. 2H).Ourmeasurements showed 12-fold
higher TRAIL staining inGFAP-positive cells and 5-fold higher
in lectin-positive cells compared with other brain cells.
In contrast, DR5 was expressed predominantly in neurons
(Fig. 3, A–E) and to some extent in OPCs (Fig. 3, F–J) 72 h after
HI. Our measurements showed 4-fold higher DR5 staining in
theNeuN-positive (Fig. 3C) and 3-fold higher staining inOlig2-
positive cells (Fig. 3H) compared with other brain cells in the
ipsilateral side of the brain. As OPCs and neurons are vulnera-
ble and severely compromised after HI, the increase of DR5
FIGURE 1. Effects of HI on the expression levels of TRAIL (A), DR5 (B), mDcTrailR1 (C), mDcTrailR2 (D), and OPG (E) in neonatal mice are shown. mRNA levels
were measured in 9- and 12-day-old sham-operated animals (white bars), contralateral (Contra; gray bars), and ipsilateral (Ipsi; black bars) hemispheres
of the brain 2, 8, 24, and 72 h after the insult. The results are expressed as fold change compared with 9-day-old sham-operated animals for every gene.
Western blot detection of TRAIL (F) and DR5 (G) protein in sham-operated (Sham, white bars), ipsilateral (I, gray bars), and contralateral hemisphere (C,
black bars) brain lysates 72 h after HI. Error bars represent average S.E. *, p 0.05; **, p 0.01; ***, p 0.001 versus corresponding contralateral side
(n  5 (A–E) and n  3 (F and G)).
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expression in these cells implicates TRAIL-DR5 signaling in
neonatal brain injury.
OGD and Inflammation Increase the Expression of TRAIL
and TRAIL Receptors in Primary Neurons and OPCs—To gain
new insights into TRAIL-mediated cell death, we investigated
TRAIL and its receptors in primary mouse neurons and pri-
mary ratOPCs in vitro. These cells were exposed to eitherOGD
and/or proinflammatory cytokines (TNF- and IFN-) to
mimic HI and the neuroinflammation relevant to perinatal
brain injury (5, 33).
Primary Neurons—Co-administration of TNF- and IFN-
induced an increase of mRNA for TRAIL after 24 and 72 h of
exposure, whereas OGD had no or little effect on TRAIL
expression alone or in combinationwith the cytokines (Fig. 4A).
The changes were confirmed at protein level by Western blot
72 h after the treatment (Fig. 4F). ThemRNAexpression ofDR5
was significantly and equally induced at 24 h by both OGD and
inflammatory cytokines, and the combination of OGD and
cytokines evoked an additive increase for DR5 expression at 24
and 72 h (Fig. 4B). ThemRNA formDcTrailR2was significantly
but moderately induced by TNF-/IFN- at 72 h (Fig. 4D). The
expression of OPGwas substantially increased by the cytokines
treatment as well (Fig. 4E). The combination of OGD TNF-
/IFN- showed a tendency to increase the expression of both
OPG and mDcTrailR2 even further but the difference was not
significant compared with TNF-/IFN- treatment alone (Fig.
4,D and E). The expression of mDcTrailR1 was not affected by
any of these conditions (Fig. 4C).
Primary OPCs—TNF-/IFN- exposure induced a marked
increase of TRAIL mRNA and protein (Fig. 5, A and D). Mean
DR5 mRNA levels were slightly higher after both OGD and
TNF-/IFN-, but these increases were not statistically signif-
icant (Fig. 5B). In addition, there was a moderate elevation of
OPG mRNA expression (Fig. 5C). OGD did not affect TRAIL
(Fig. 5A) and OPG (Fig. 5C); in fact, we observed a decrease in
their expression whenOGDwas combined with the proinflam-
matory cytokines, reaching significance when compared with
TNF-/IFN- alone in the case of OPG (Fig. 5C). In addition,
FIGURE 2. Representative images of conventional (A, D, F, and I) and confocal
(B, E, G, and J) fluorescence microscopy show TRAIL (green) immunolabeling
in paraffin sections from ipsilateral (Ipsi; A, B, F, and G) and contralateral (Con-
tra; D, E, I, and J) hemispheres of the mouse brain at 72 h after HI. There was
TRAIL immunoreactivity in GFAP-positive (red) astroglia (A–E) and lectin-pos-
itive (red) microglia (F–J). GFAP- and lectin-positive cells exhibited stronger
TRAIL immunostaining than the GFAP- and lectin-negative cells (C and H).
Scale bar, 30 m (A, D, F, and I) and 10 m (B, E, G, and J). Typical GFAP- or
lectin-positive cells are indicated by arrows.
FIGURE 3. Conventional (A, D, F, and I) and confocal (B, E, G, and J) fluo-
rescence microscopy images demonstrating DR5 (green) immuno-
staining in NeuN-positive (red) neurons (A–E) and Olig2-positive (red)
oligodendroglial cells (F–J) in the brain at 72 h after HI in neonatal mice.
The DR5 immunostainingwasmore pronounced in the ipsilateral (Ipsi) hemi-
sphere (A, B, F,G) comparedwith the non-injured contralateral (Contra;D, E, I,
and J) hemisphere. NeuN- and Olig2-positive cells immunostained more
intensely for TRAIL than the NeuN- and Olig2-negative cells (C and H). Scale
bar, 30 m (A, D, F, and I) and 10 m (B, E, G, and J). Typical Olig2- or NeuN-
positive cells are indicated by arrows.
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we assessed the expression of TRAIL in the primary rat astro-
cytes (Fig. 6A) and microglia (Fig. 6B) and found significant
increases in expression of TRAIL in both cell types after TNF-
and IFN- treatment, confirming the immunohistochemistry
data from the animal model.
Recombinant TRAIL Is Toxic for PrimaryNeurons but Not for
Primary OPCs—To determine the toxicity of TRAIL, primary
cells were treated with recombinant TRAIL. Cell viability was
evaluated by methylthiazolyldiphenyl-tetrazolium bromide
assay (Fig. 7, A and C) and by counting cleaved caspase-3-neg-
ative nuclei (Fig. 7,B andD) 48 h after the exposure. In addition,
TRAIL treatment was combined with OGD and inflammatory
cytokine exposure to assess possible interactions. Recombinant
TRAIL decreased neuronal viability to 80% by 48 h of exposure,
and its toxicitywas not aggravated furtherwhen combinedwith
TNF-/IFN-. The proinflammatory cytokine treatment alone
had no toxic effects on the neurons. OGD significantly reduced
neuronal survival compared with control, and addition of
TRAIL further enhanced OGD-induced neuronal death (Fig. 7,
A and B). Proinflammatory cytokines exerted similar toxicity
under OGD conditions but did not further exacerbate the neu-
ronal death induced by OGDTRAIL (Fig. 7, A and B). We
verified the specificity of TRAIL toxicity by treating the cells
with denatured TRAIL (dtTRAIL). The treatment with
dtTRAIL did not induce any toxicity alone or in combination
with OGD or TNF-/IFN- compared with its corresponding
control. In summary, TRAIL exerted significant toxicity under
all conditions, supporting TRAIL participation in the develop-
ment of neuronal death after HI.
In primary OPC cultures, TNF-/IFN- and OGD induced
50% cell death. Co-exposure with cytokines and OGD
increased injury further as compared with either insult alone
with up to 80% of the OPCs undergoing cell death (Fig. 7,C and
D). When compared with neurons, OPCs appear to be equally
sensitive toOGDbutmore sensitive toTNF-/IFN-. Contrary
to our expectations, TRAIL was not toxic when administered
alone, and it did not modulate OPC cell death induced by cyto-
kines or OGD (Fig. 7, C and D).
FIGURE 4. Shown is the effect of OGD and IFN-/TNF- treatments on expression levels of TRAIL (A), DR5 (B), mDcTrailR1 (C), mDcTrailR2 (D), and OPG (E) in
primary neurons.mRNA levels weremeasured at 2 h (white bars), 24 h (gray bars), and 72 h (black bars) after exposure. The results are expressed as fold change
comparedwith non-treated control cells. Error bars representmean S.E., *,p 0.05; **,p 0.01; ***,p 0.001; #,p 0.05 versus corresponding controls (n
4). TRAIL expression levels were confirmed at protein level by Western blot (F).
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DISCUSSION
In this study, we have shown for the first time that expression
ofTRAIL and theTRAIL receptorDR5 aremarkedly induced in
the neonatal brain after HI in vivo and, interestingly, that these
changes are accompanied by overexpression of mDcTrailR2
and OPG. TRAIL was predominantly expressed by microglia
and astroglia in agreement with previous reports in the adult
brain after ischemia (22) but was also detected in neurons and
OPCs. DR5 was expressed primarily on neurons and OPCs, i.e.
in cells highly vulnerable to HI insults (34). These in vivo data
suggested that TRAIL is produced and released by activated
glial cells whereupon it could exert toxic effects on OPCs and
neurons, unless TRAIL is neutralized byOPGandmDcTrailR2.
Qualitatively, the changes in expression of TRAIL, DR5, OPG,
and mDcTrailR2 in neuronal cultures were similar to changes
observed in vivo.
Another important finding from our studies is that the TNF-
/IFN- treatment more potently induced TRAIL and OPG
thanOGD in both neuronal andOPCcultures. In contrast, DR5
was overexpressed after OGD in neurons, and the levels were
further enhanced if OGD was combined with cytokine admin-
istration. DR5was poorly expressed inOPC cultures andwas not
induced by any of the in vitro exposures (Fig. 5B). Furthermore, in
OPCs, we observed that OGD additive treatment significantly
attenuated theOPGup-regulation caused byTNF-/IFN- treat-
ment alone (Fig. 5C). It has been reported that mature oligoden-
drocytes hardly expressed TRAIL death receptors but that they
were markedly up-regulated in active multiple sclerosis lesions
(25) and that the expression of TRAIL death receptors can be pro-
voked by p53 overexpression (35). However, no studies to date
have evaluated the influence of OGD and cytokine treatment on
OPCTRAIL receptor expression.
FIGURE 5. Shown is the effect ofOGDand IFN-/TNF-exposureonexpression levels of TRAIL (A), DR5 (B), andOPG (C) in primaryOPCs.mRNA levelsweremeasured
withquantitativeRT-PCR48hafter the treatment. The resultsareexpressedas foldchangecomparedwithnon-treatedcontrol cells.Errorbars representmeanS.E.*,
p 0.05; ***, p 0.001 versus corresponding controls (n 5). TRAIL expression levels were confirmed at protein level byWestern blot (D).
FIGURE 6. Effect of OGD and IFN-/TNF- treatments on expression levels of TRAIL in primary astrocytes (A) and microglia (B). mRNA levels were
measured at 48 h after exposure. The results are expressed as fold change compared with non-treated control cells. Error bars represent mean S.E. ***, p
0.001; #, p 0.05 versus corresponding controls (n 5).
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We found that recombinant TRAIL treatment is toxic for
neurons but not for OPCs. Furthermore, the susceptibility of
neurons to TRAIL was not further enhanced by co-exposure to
cytokines and/or OGD. This could be explained by the pro-
nounced increase ofmDcTrailR2 and especially ofOPG as both
could bind TRAIL and limit its toxicity on DR5 (18, 20). Simi-
larly, cytokine treatment was not toxic to neurons despite
increasing the expression of both TRAIL and DR5. We suspect
that the increased expression of the decoy receptors OPG and
mDcTrailR2 after cytokine treatment prevented TRAIL toxic-
ity. After OGD, however, the TNF-/IFN- treatment was
toxic for the neurons. This finding corroborates animal models
in which the combination of HI with inflammation (LPS treat-
ment) increases the severity of the injury (36) and with in vitro
studies showing increased TNF- toxicity after OGD (37).
In our OPC experiments, TRAIL exposure did not lead to or
increase the vulnerability of the OPCs to any of the conditions.
The TNF-/IFN- treatment, however, proved to be highly
toxic to OPCs, which confirms previously published data (38).
More importantly, OGD exacerbated this effect as the toxicity
of OGD cytokine treatment compared with OGD alone was
significantly higher than the toxic effect of cytokine treatment
compared with non-treated controls (Fig. 7, C and D). This
finding once again agrees with animal models (36, 39) and
shows for the first time the additive toxic effect of OGD and
cytokine treatment on OPCs.
The lack of toxicity of TRAIL in OPCs alone, or in combina-
tionwithOGD/cytokines, is best explained by the fact that DR5
is poorly expressed and not induced significantly by these stim-
uli in OPC cultures. Alternatively, the high levels of OPG, espe-
cially after TNF-/IFN- exposure could have neutralizedOPC
sensitivity to TRAIL. However, this does not explain why
TRAIL was not toxic when administered alone or in combina-
tion with OGD.
We found increased expression of DR5 onOPCs in vivo after
HI by immunofluorescence microscopy. It is likely that this
increased expression is induced by microglial and astroglial
derived signals, and it remains possible that TRAIL is toxic to
OPCs in vivo. Additional in vivo studies using soluble TRAIL
receptors to block TRAIL activity (22) or TRAIL or conditional
DR5 knock-out animals may shed light on this issue.
Summarizing these findings, we conclude that TRAIL signal-
ing is important for neuronal cell death after neonatal HI. We
have shown that bothTRAIL andDR5 are dramatically induced
after HI, and our in vitro studies show that TRAIL itself is toxic
to neurons. Another key finding is that neurons andOPCs have
FIGURE 7. Effect of OGD, IFN-/TNF-, TRAIL, and dtTRAIL treatment on cell survival measured bymethylthiazolyldiphenyl-tetrazolium bromide (A
and C) and counting cleaved caspase-3-negative cells (B and D) 48 h after the insult. Primary neurons treated with IFN-/TNF-, TRAIL, or dtTRAIL and
combination or subjected to OGD and treatedwith IFN-/TNF-, TRAIL, or dtTRAIL and a combination (A and B). Primary OPC treatedwith IFN-/TNF-, TRAIL,
or dtTRAIL and a combination or subjected to OGD and treated with IFN-/TNF-, TRAIL, or dtTRAIL and a combination (C andD). The results are expressed as
percent change of non-treated control cells. Error bars represent mean  S.E. Statistical significance was calculated by comparing every treatment versus
control. *, p 0.05; **, p 0.01; ***, p 0.001 versus corresponding controls.
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different sensitivities to TRAIL, OGD, and proinflammatory
cytokines. The fact that OPCs survive after TRAIL treatment
does not rule out the possibility that TRAIL is affecting other
biological processes such as differentiation and myelination,
critical in the context of the developing brain (40). Further stud-
ies are required to fully understand the role of TRAIL signaling
in the developing brain after HI injury.
REFERENCES
1. Fatemi, A., Wilson, M. A., and Johnston, M. V (2009) Hypoxic-ischemic
encephalopathy in the term infant. Clin. Perinatol. 36, 835–858
2. Volpe, J. J. (2011) Systemic inflammation, oligodendroglial maturation,
and the encephalopathy of prematurity. Ann. Neurol. 70, 525–529
3. Thornton, C., Rousset, C. I., Kichev, A., Miyakuni, Y., Vontell, R., Babura-
mani, A. A., Fleiss, B., Gressens, P., and Hagberg, H. (2012) Molecular
mechanisms of neonatal brain injury. Neurol. Res. Int. 2012, 506320
4. Hagberg, H., Gressens, P., and Mallard, C. (2012) Inflammation during
fetal and neonatal life: implications for neurologic and neuropsychiatric
disease in children and adults. Ann. Neurol. 71, 444–457
5. Hagberg, H., and Mallard, C. (2005) Effect of inflammation on central
nervous system development and vulnerability. Curr. Opin. Neurol. 18,
117–123
6. Bona, E., Andersson, A. L., Blomgren, K., Gilland, E., Puka-Sundvall, M.,
Gustafson, K., and Hagberg, H. (1999) Chemokine and inflammatory cell
response to hypoxia-ischemia in immature rats. Pediatr. Res. 45, 500–509
7. Taylor, D. L., Jones, F., Kubota, E. S., and Pocock, J. M. (2005) Stimulation
of microglial metabotropic glutamate receptor mGlu2 triggers tumor ne-
crosis factor alpha-induced neurotoxicity in concert with microglial-de-
rived Fas ligand. J. Neurosci. 25, 2952–2964
8. Hoffmann, O., Zipp, F., and Weber, J. R. (2009) Tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) in central nervous system in-
flammation. J. Mol. Med. 87, 753–763
9. Yepes, M., Brown, S. A., Moore, E. G., Smith, E. P., Lawrence, D. A, and
Winkles, J. A. (2005) A soluble Fn14-Fc decoy receptor reduces infarct
volume in amurinemodel of cerebral ischemia.Am. J. Pathol.166, 511–20
10. McGuire, C., Beyaert, R., and van Loo, G. (2011) Death receptor signalling
in central nervous system inflammation and demyelination. Trends Neu-
rosci. 34, 619–628
11. Kendall, G. S., Hristova, M., Hirstova, M., Horn, S., Dafou, D., Acosta-
Saltos, A., Almolda, B., Zbarsky, V., Rumajogee, P., Heuer, H., Castellano,
B., Pfeffer, K., Nedospasov, S. A., Peebles, D. M., and Raivich, G. (2011)
TNF gene cluster deletion abolishes lipopolysaccharide-mediated sensiti-
zation of the neonatal brain to hypoxic ischemic insult. Lab. Invest. 91,
328–341
12. Felderhoff-Mueser, U., Taylor, D. L., Greenwood, K., Kozma, M., Stibenz,
D., Joashi, U.C., Edwards, A.D., andMehmet,H. (2000) Fas/CD95/APO-1
can function as a death receptor for neuronal cells in vitro and in vivo and
is upregulated following cerebral hypoxic-ischemic injury to the develop-
ing rat brain. Brain Pathol. 10, 17–29
13. Graham, E. M., Sheldon, R. A., Flock, D. L., Ferriero, D. M., Martin, L. J.,
O’Riordan, D. P., and Northington, F. J. (2004) Neonatal mice lacking
functional Fas death receptors are resistant to hypoxic-ischemic brain
injury. Neurobiol. Dis. 17, 89–98
14. Pan, G., O’Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and
Dixit, V. M. (1997) The receptor for the cytotoxic ligand TRAIL. Science
276, 111–113
15. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh,
J. Y., Boiani, N., Timour,M. S., Gerhart,M. J., Schooley, K. A., Smith, C. A.,
Goodwin, R. G., and Rauch, C. T. (1997) TRAIL-R2: a novel apoptosis-
mediating receptor for TRAIL. EMBO J. 16, 5386–5397
16. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M.,
Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., God-
dard, A. D., Godowski, P., and Ashkenazi, A. (1997) Control of TRAIL-
induced apoptosis by a family of signaling and decoy receptors. Science
277, 818–821
17. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Bald-
win,D., Yuan, J., Gurney,A., Goddard,A.D.,Godowski, P., andAshkenazi,
A. (1997) A novel receptor for Apo2L/TRAIL contains a truncated death
domain. Curr. Biol. 7, 1003–1006
18. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman,
C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A.,
James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. (1998) Osteopro-
tegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273,
14363–14367
19. Bossen, C., Ingold, K., Tardivel, A., Bodmer, J. L., Gaide, O., Hertig, S.,
Ambrose, C., Tschopp, J., and Schneider, P. (2006) Interactions of tumor
necrosis factor (TNF) and TNF receptor family members in the mouse
and human. J. Biol. Chem. 281, 13964–13971
20. Schneider, P., Olson, D., Tardivel, A., Browning, B., Lugovskoy, A., Gong,
D., Dobles, M., Hertig, S., Hofmann, K., Van Vlijmen, H., Hsu, Y. M.,
Burkly, L. C., Tschopp, J., and Zheng, T. S. (2003) Identification of a new
murine tumor necrosis factor receptor locus that contains two novel mu-
rine receptors for tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL). J. Biol. Chem. 278, 5444–5454
21. Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S., and El-Deiry,W. S. (1999)
Molecular cloning and functional analysis of the mouse homologue of the
KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) death receptor. Cancer Res. 59, 2770–2775
22. Cui, M., Wang, L., Liang, X., Ma, X., Liu, Y., Yang, M., Liu, K., Wei, X.,
Zhou, Z., Chen, Y. H., and Sun,W. (2010) Blocking TRAIL-DR5 signaling
with soluble DR5 reduces delayed neuronal damage after transient global
cerebral ischemia. Neurobiol. Dis. 39, 138–147
23. Krajewska, M., You, Z., Rong, J., Kress, C., Huang, X., Yang, J., Kyoda, T.,
Leyva, R., Banares, S., Hu, Y., Sze, C. H., Whalen, M. J., Salmena, L.,
Hakem, R., Head, B. P., Reed, J. C., and Krajewski, S. (2011) Neuronal
deletion of caspase 8 protects against brain injury in mouse models of
controlled cortical impact and kainic acid-induced excitotoxicity. PLoS
One 6, e24341
24. Clarke, P., Leser, J. S., Quick, E. D., Dionne, K. R., Beckham, J. D., andTyler,
K. L. (2014) Death receptor mediated apoptotic signaling is activated in
the brain following infection with West Nile virus in the absence of a
peripheral immune response. J. Virol. 88, 1080–1089
25. Cannella, B., Gaupp, S., Omari, K. M., and Raine, C. S. (2007) Multiple
sclerosis: death receptor expression and oligodendrocyte apoptosis in es-
tablished lesions. J. Neuroimmunol. 188, 128–137
26. Huang, Z., Song, L., Wang, C., Liu, J. Q., and Chen, C. (2011) Hypoxia-
ischemia upregulates TRAIL and TRAIL receptors in the immature rat
brain. Dev. Neurosci. 33, 519–530
27. Rice, J. E., 3rd, Vannucci, R. C., and Brierley, J. B. (1981) The influence of
immaturity on hypoxic-ischemic brain damage in the rat. Ann. Neurol. 9,
131–141
28. Hedtjärn, M., Leverin, A. L., Eriksson, K., Blomgren, K., Mallard, C., and
Hagberg, H. (2002) Interleukin-18 involvement in hypoxic-ischemic brain
injury. J. Neurosci. 22, 5910–5919
29. Sheldon, R. A., Sedik, C., and Ferriero, D. M. (1998) Strain-related brain
injury in neonatal mice subjected to hypoxia-ischemia. Brain Res. 810,
114–122
30. Thornton, C., Bright, N. J., Sastre,M.,Muckett, P. J., andCarling, D. (2011)
AMP-activated protein kinase (AMPK) is a tau kinase, activated in re-
sponse to amyloid -peptide exposure. Biochem. J. 434, 503–512
31. Levison, S. W., and McCarthy, K. D. (1991) Characterization and partial
purification of AIM: a plasma protein that induces rat cerebral type 2
astroglia from bipotential glial progenitors. J. Neurochem. 57, 782–794
32. McCarthy, K. D., and de Vellis, J. (1980) Preparation of separate astroglial
and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85,
890–902
33. Dammann, O., and Leviton, A. (1997) Maternal intrauterine infection,
cytokines, and brain damage in the preterm newborn. Pediatr. Res. 42,
1–8
34. Volpe, J. J. (2009) Brain injury in premature infants: a complex amalgam of
destructive and developmental disturbances. Lancet Neurol. 8, 110–124
35. Wosik, K., Antel, J., Kuhlmann, T., Brück,W.,Massie, B., andNalbantoglu,
J. (2003) Oligodendrocyte injury in multiple sclerosis: a role for p53.
J. Neurochem. 85, 635–644
36. Eklind, S., Mallard, C., Leverin, A. L., Gilland, E., Blomgren, K., Mattsby-
TRAIL Signaling in Immature CNS after HI and Inflammation
9438 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 13•MARCH 28, 2014
 at RO
Y
A
L V
ET CO
LL./LIBRA
RIA
N
 on M
ay 3, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Baltzer, I., and Hagberg, H. (2001) Bacterial endotoxin sensitizes the imma-
ture brain to hypoxic–ischaemic injury. Eur. J. Neurosci. 13, 1101–1106
37. Markus, T., Cronberg, T., Cilio, C., Pronk, C., Wieloch, T., and Ley, D.
(2009) Tumor necrosis factor receptor-1 is essential for LPS-induced sen-
sitization and tolerance to oxygen-glucose deprivation inmurine neonatal
organotypic hippocampal slices. J. Cereb. Blood Flow Metab. 29, 73–86
38. Andrews, T., Zhang, P., and Bhat, N. R. (1998) TNFalpha potentiates
IFNgamma-induced cell death in oligodendrocyte progenitors. J. Neuro-
sci. Res. 54, 574–583
39. Wang, X., Hagberg, H., Nie, C., Zhu, C., Ikeda, T., and Mallard, C. (2007)
Dual role of intrauterine immune challenge on neonatal and adult brain
vulnerability to hypoxia-ischemia. J. Neuropathol. Exp. Neurol. 66, 552–
561
40. Favrais, G., van de Looij, Y., Fleiss, B., Ramanantsoa, N., Bonnin, P., Stol-
tenburg-Didinger, G., Lacaud, A., Saliba, E., Dammann, O., Gallego, J.,
Sizonenko, S., Hagberg, H., Lelièvre, V., and Gressens, P. (2011) Systemic
inflammation disrupts the developmental program of white matter. Ann.
Neurol. 70, 550–565
TRAIL Signaling in Immature CNS after HI and Inflammation
MARCH 28, 2014•VOLUME 289•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 9439
 at RO
Y
A
L V
ET CO
LL./LIBRA
RIA
N
 on M
ay 3, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Wood, Pierre Gressens, Claire Thornton and Henrik Hagberg
Anton Kichev, Catherine I. Rousset, Ana A. Baburamani, Steven W. Levison, Teresa L.
Inflammation
Cell Death in the Immature Central Nervous System after Hypoxia-Ischemia and 
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Signaling and
doi: 10.1074/jbc.M113.512350 originally published online February 7, 2014
2014, 289:9430-9439.J. Biol. Chem. 
  
 10.1074/jbc.M113.512350Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/289/13/9430.full.html#ref-list-1
This article cites 40 references, 12 of which can be accessed free at
 at RO
Y
A
L V
ET CO
LL./LIBRA
RIA
N
 on M
ay 3, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
